mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
- Tim Meyer
- , Daniel H. Palmer
- , Ann Lii Cheng
- , Julia Hocke
- , Arsène Bienvenu Loembé
- , Chia Jui Yen
Research output: Contribution to journal › Article › peer-review
71
Link opens in a new tab
Citations
(Scopus)